Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28676196 | 1.00 | RET (0.46) | RETPANK3RIPK1ACHEDDB1 | |
| SCHEMBL7394146 | 0.85 | PANK3 (0.42) | RETPANK3ACHEDDB1CRBN | |
| SCHEMBL22389879 | 0.85 | PANK3 (0.50) | PANK3RIPK1ACHECTSSCHRM2 | |
| SCHEMBL22389947 | 0.83 | RET (0.44) | RETGPR119 | |
| SCHEMBL28562329 | 0.82 | RET (0.42) | RETACHEDDB1CRBNGPR119 | |
| SCHEMBL6701202 | 0.82 | CYP3A4 (0.50) | RETACHEGPR119 | |
| SCHEMBL28685652 | 0.80 | RET (0.45) | RETGPR119 | |
| SCHEMBL31318812 | 0.80 | RET (0.45) | RETGPR119 | |
| SCHEMBL25834000 | 0.78 | PANK3 (0.47) | PANK3RIPK1CTSSCHRM2ACACB | |
| SCHEMBL25237876 | 0.78 | ACHE (0.58) | PANK3ACHEDDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113795483-B | Carboxamide-pyrimidine derivatives as SHP2 antagonists | 默克专利有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-11 | — | — | US | disclosed |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696916-B2 | Carboxamide-pyrimidine derivatives as SHP2 antagonists | PTPN5, PTPN2, PTPN1 | RET 60/4885PANK3 1328/4885RIPK1 447/4885 |
| US-20220362244-A1 | CARBOXAMIDE-PYRIMIDINE DERIVATIVES AS SHP2 ANTAGONISTS | PTPN5, PTPN2, PTPN1 | RET 60/4885PANK3 1328/4885RIPK1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.